Skip to main content
Premium Trial:

Request an Annual Quote

Frank Gentile

Premium

Frank Gentile has left his position as vice president for technology program management at Millennium Pharmaceuticals to join Boston-based investment firm Hambrecht & Quist Capital Management as vice president of research. Prior to working at Millennium, Gentile was vice president for product development at Curis. He is also an adjunct associate professor of biotechnology at Brown University. Gentile holds a BE from the Cooper Union for the Advancement of Science and Art and a PhD in chemical engineering from MIT.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.